SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Patel NP, Lavengood RW. Renal cell cancer: natural history and results of treatment. J Urol. 1997; 119: 722726.
  • 2
    Krown SE. Cytokines: interferons and interferon inducers in cancer treatment. Semin Oncol. 1986; 13: 207217.
  • 3
    Maldazys JD, deKernion, JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1996; 136: 376379.
  • 4
    Atzpodien J, Korfer A, Franks CR, et al. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990; 335: 15091512.
  • 5
    Atzpodien J, Lopez HE, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995; 13: 497501.
  • 6
    Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271: 907913.
  • 7
    Lissoni P, Barni S, Ardizzoia A, et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer. 1992; 28: 9296.
  • 8
    Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992; 10: 11191123.
  • 9
    Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987; 14: 3642.
  • 10
    Lopez-Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996; 155: 1925.
  • 11
    Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil [see comments]. J Urol. 1996; 156: 1821.
  • 12
    Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomised clinical trial. Br J Cancer. 2001; 85: 11301136.
  • 13
    Motzer RJ, Schwartz L, Law TM, et al. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a Phase II trial and interactions in vitro. J Clin Oncol. 1995; 13: 19501957.
  • 14
    Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alpha-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000; 18: 29722980.
  • 15
    Buer J, Probst M, Ganser A, Atzpodien J. Response to 13-cis-retinoic acid plus interferon alpha-2a in two patients with therapy-refractory advanced renal cell carcinoma [letter]. J Clin Oncol. 1995; 13: 26792680.
  • 16
    Atzpodien J, Poliwoda H, Kirchner H. Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol. 1991; 18: 108112.
  • 17
    Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol. 2000; 27: 204212.
  • 18
    Ravaud A, Audhuy B, Escudier B, et al. Subcutaneous interleukin-2, interferon alpha-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter Phase II trial. Groupe Francais d'Immunotherapie. J Clin Oncol. 1998; 16: 27282732.
  • 19
    Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff EP. Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell carcinoma. Eur Urol. 1999; 35: 204209.
  • 20
    Tourani JM, Pfister C, Berdah JF, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alpha administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized Phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol. 1998; 16: 25052513.
  • 21
    Atzpodien J, Kirchner H, Bergmann L, et al. 13 cis-retinoic acid, IFN-alpha, IL-2 and chemotherapy in advanced renal cell carcinoma: results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Immunotherapy Group (DGCIN). Proc Am Soc Clin Oncol. 1999; 17: 27.
  • 22
    Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter Phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998; 6: 18201825.
  • 23
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335: 865875.
  • 24
    Buer J, Probst M, Duensing S, et al. Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. Cancer Biother Radiopharm. 1997; 12: 143147.
  • 25
    Atzpodien J, Kirchner H, Duensing S, et al. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastin, and 13-cis-retinoic acid. World J Urol. 1995; 13: 174177.